{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-011129","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.672882+00:00","generated_at":"2026-06-29T16:22:30.054754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Altimmune Q2 net loss $24.8M; ALT-801 Phase 1 data expected Sept 2021","bullets":["Q2 net loss $24.8M ($0.60/shr) vs $16.8M ($0.94/shr) prior year; revenue $0.1M down from $0.7M.","Cash, equivalents & investments $217.9M; raised $18.2M net via ATM in Q2.","Recorded $8.1M impairment on construction-in-progress for terminated COVID-19 vaccine program.","ALT-801 Phase 1 12-week data readout on three dose cohorts expected September 2021.","IND for NASH on track for Q3 2021; obesity IND planned Q4 2021; Phase 2 trials targeted early 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-011129","json":"https://secwatch.observer/filing/0001558370-21-011129.json","markdown":"https://secwatch.observer/filing/0001558370-21-011129.md","text":"https://secwatch.observer/filing/0001558370-21-011129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000155837021011129/0001558370-21-011129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000155837021011129/alt-20210810x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T16:22:30.054754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}